The U.S. Food and Drug Administration (FDA) has given approval to TREMFYA® (guselkumab) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in children. This groundbreaking approval makes TREMFYA® the first and only IL-23 inhibitor available for pediatric patients, offering a new ray of hope for thousands of children affected by these chronic conditions.
Roche is set to present a wealth of new data at the 41st ECTRIMS Congress, highlighting the expanding benefits of its flagship multiple sclerosis therapy, OCREVUS® (ocrelizumab). New findings demonstrate a significant reduction in disability progression for adults with advanced primary progressive MS (PPMS) and reinforce its safety for pregnant women and their infants. The presentation will also include the first comparative data for OCREVUS in pediatric MS. Alongside these updates, Roche will showcase promising two-year results for its investigational oral BTK inhibitor, fenebrutinib, which showed near-complete suppression of disease activity in patients with relapsing MS ahead of pivotal Phase III readouts.
Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new subcutaneous (at-home) induction option for TREMFYA® (guselkumab) for adults with moderately to severely active ulcerative colitis. This approval, based on the successful Phase 3 ASTRO trial, makes TREMFYA the first and only IL-23 inhibitor to offer a completely subcutaneous regimen for both induction and maintenance, providing a significant new convenience for patients managing their condition.
Eli Lilly announced results from the Phase 3 ATTAIN-2 trial, where its oral GLP-1 receptor agonist orforglipron provided substantial weight loss and improved A1C for adults living with obesity and type 2 diabetes demonstrating efficacy and safety consistent with injectable medicines, and moving toward regulatory approval.
Semaglutide has transformed obesity and diabetes care, offering significant weight loss and glucose control with once-weekly dosing. Here’s a look at its clinical promise and expanding role in medicine.
Eli Lilly’s once-weekly insulin, efsitora alfa, has shown promising results in Phase 3 clinical trials. The innovative treatment demonstrated A1C reductions comparable to daily basal insulins, with a consistent safety profile.
In addition, the research showed an 80% reduction in the hospitalization risk of cardiovascular disease in individuals with Type 1 diabetes who did not have a previous history of such illnesses.
Many Americans suffer from long-term inflammatory skin disorders that have no known etiology and frequently no effective treatments other than symptom control. A recent study [Read More…]
According to the study, even in the absence of established triggers for these antibodies, such as blood thinners (heparin) or previous vaccinations.
A biotech startup that was spun off from UC San Diego uses deep learning to screen for potential antibiotic candidates as a TB outbreak spreads in Kansas.
